Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes.
We report on a 33-year-old male patient with generalized acquired lipodystrophy, insulin resistant diabetes mellitus and acanthosis nigricans (Lawrence Syndrome). First probable symptoms of lipodystrophy (weight loss, shrinkage of subcutaneous fatty tissue, and loss of muscular strength) became evident three years ago, with the onset of diabetes mellitus occurring about six months later. The patient suffered from the following clinical symptoms: IDDM with increasing insulin-requirement, extreme reduction of fatty tissue, fatty liver hepatitis with elevated liver enzymes, glomerulopathy, muscular and neuropathic pains, as well as hypertriglyceridaemia. A basal C-peptide concentration is rather high. Definitely, the endogenous insulin secretion is increased. In other words, insulin resistance is documented. In an effort to identify the pathogenetic mechanisms of lipoatrophic diabetes mellitus in this patient and to develop a therapeutic strategy, antibodies against different tissues and endocrinologic regulation were investigated. It was possible to demonstrate the presence of serum autoantibodies against lipocytes of the subcutis and other tissues, against hepatic stellate cells, together with autoantibodies against different endocrine organs. By studying the basis of diabetic abnormalities relating to the growth hormone (GH), the insulin-like growth factor (IGF) dynamics in this patient, i.e. reductions of GH, IGF-I, IGF-II, IGF-Binding protein (IGF-BP) 2 and IGF-BP 3, were detected. An immunosuppressive treatment strategy was not beneficial.
Hübler
A
A
Department of Internal Medicine IV, Friedrich-Schiller-University of Jena, Germany.
Abendroth
K
K
Keiner
T
T
Stöcker
W
W
Kauf
E
E
Hein
G
G
Stein
G
G
D017667:Adipocytes / Q000166:cytology* / Q000276:immunology / Q000473:pathology; D000328:Adult; D001323:Autoantibodies / Q000276:immunology*; D002462:Cell Membrane / Q000276:immunology; D003923:Diabetes Mellitus, Lipoatrophic / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D008297:Male; D013002:Somatomedins / Q000276:immunology / Q000378:metabolism*
D001323:Autoantibodies; D013002:Somatomedins